In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Align: Selling Innovation to Late Adopters

Executive Summary

Dentistry and orthodontics have been largely untouched by significant recent product development, and thus have not attracted much interest from medical device venture investors. Align Technology emerged from an unlikely source--two second-year Stanford business students with no previous start-up experience who were able to attract major venture backers. The founders' idea was that, by using advanced product design and manufacturing processes, the company could produce the Invisalign system of removable, clear plastic dental appliances that, for certain orthodontic patients, particularly adults--a large untapped market--could take the place of traditional metal braces. The company's founders invested heavily in direct-to-consumer marketing that resulted in patients favoring the product before many doctors were familiar with it. After a successful IPO, Align's channel problems, along with other missteps, drove the company's stock down to the one-dollar range. A new management team has restructured the company and implemented a more focused strategy. For Align, traditional braces are now no longer the enemy. Instead, the company promotes Invisalign as another tool in the orthodontists' and dentists' armamentarium, an approach that appears to be capturing support among customer groups not known for embracing new technology.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel